Detail

Basic Information Clinical Results Relationship Graph

Basic Information

GTO ID	GTC0563
Trial ID	NCT05184127
Disease	COVID-19
Altered gene	RdRp
Therapeutic/Target gene	Target gene
Therapy	siRNA
Treatment	MIR 19\|siR-7-EM/KK-46
Co-treatment	Favipiravir\|Umifenovir\|Remdesivir\|convalescent plasma\|interferon α-2b
Phase	Phase2
Recruitment status	Completed
Title	Open Multicenter Controlled Clinical Trial to Evaluate Safety and Efficacy of Aerosolized MIR 19 Inhalation in Patients With Moderate COVID-19 Who Did Not Require Treatment in the Intensive Care Unit.
Year	2021
Country	Russian Federation
Company sponsor	National Research Center - Institute of Immunology Federal Medical-Biological Agency of Russia
Other ID(s)	SiCoV/KK46-2021_CSR

Vector information

Vector	GalNAc

Clinical Result

Cohort1: MIR 19_dose level 1

Administration route	inhalation
Dosage	3.7 mg/day
Pts	52
Age	Adult, Older_Adult
Adverse reactions	5/52(COVID-19 pneumonia)
References	PMID: 36721963

Cohort2: MIR 19_dose level 2

Administration route	inhalation
Dosage	11.1 mg/day
Pts	52
Age	Adult, Older_Adult
Adverse reactions	2/52(COVID-19 pneumonia)
References	PMID: 36721963

Cohort3: Standard COVID-19 therapy

Administration route	None
Pts	52
Age	Adult, Older_Adult
Adverse reactions	4/52(COVID-19 pneumonia)
References	PMID: 36721963

Relationship Graph

Overview of Knowledge Graph